Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease

Oncol Res Treat. 2014;37(6):355-62. doi: 10.1159/000362631. Epub 2014 Apr 17.

Abstract

Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue. This review focuses on soft tissue sarcoma and covers general topics such as the epidemiology, age distribution, site of disease, histogenesis, histological subtypes, prognosis and outcome of treatment. In more detail, the article reviews current systemic treatment standards and selected adverse events of agents such as doxorubicin, ifosfamide, trabectedin and pazopanib, and briefly highlights some drugs that are used off-label in specific subtypes of sarcoma.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Dioxoles / administration & dosage*
  • Doxorubicin / administration & dosage*
  • Evidence-Based Medicine
  • Humans
  • Ifosfamide / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Sarcoma / drug therapy*
  • Sarcoma / pathology*
  • Sulfonamides / administration & dosage*
  • Tetrahydroisoquinolines / administration & dosage*
  • Trabectedin
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Dioxoles
  • Pyrimidines
  • Sulfonamides
  • Tetrahydroisoquinolines
  • pazopanib
  • Doxorubicin
  • Trabectedin
  • Ifosfamide